Estimation of single-dose varicella vaccine effectiveness in South Korea using mathematical modeling

Hum Vaccin Immunother. 2022 Nov 30;18(5):2085468. doi: 10.1080/21645515.2022.2085468. Epub 2022 Jun 15.

Abstract

In South Korea, despite the implementation of a universal single-dose vaccination program for children aged 12-15 months in 2005, the varicella incidence rate remains significant. Prior case-control studies have reported that currently used varicella vaccines are extremely inefficacious. We estimated vaccine effectiveness (VE) by fitting a dynamic transmission model to age-specific varicella incidence data from 2007 to 2015 and available vaccine coverage data. The initial vaccine efficacy and primary failure rates were estimated to be 61.1% and 38.9%, respectively. The average duration of protection was 21.4 years. The mean VE [(1-relative risk) %] for the simulated data of 2004-2014 birth cohorts decreased from 59.8% to 50.7% over 9 years. This mathematical modeling study demonstrated that the single-dose vaccine exhibits moderate effectiveness, and a high proportion of primary failure could be a main cause of breakthrough infections. Therefore, a two-dose vaccination strategy should be considered.

Keywords: South Korea; Varicella; immunity waning; mathematical modeling; vaccine effectiveness.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, Viral
  • Chickenpox Vaccine*
  • Chickenpox* / epidemiology
  • Chickenpox* / prevention & control
  • Child
  • Herpesvirus 3, Human
  • Humans
  • Republic of Korea / epidemiology
  • Vaccination
  • Vaccine Efficacy
  • Vaccines, Attenuated

Substances

  • Chickenpox Vaccine
  • Vaccines, Attenuated
  • Antigens, Viral

Grants and funding

This work was supported by the National Research Foundation of Korea (NRF) under Grant [2018R1A2B6006178]; and Korea Government (MSIT) under Grant [NRF-2020R1A2C1A01010775].